---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-002421"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2022-03-01T23:59:59+00:00"
generated_at: "2026-06-27T03:04:31.090027+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Crinetics appoints James Hassard as Chief Commercial Officer

## Summary
- James Hassard appointed CCO effective Feb 28, 2022; base salary $425,000, target bonus 40%.
- Will receive option to purchase 160,000 shares (25% vest Feb 28, 2023; balance monthly over 3 years).
- Hassard brings 30+ years biotech commercial experience; previously CCO at Arrowhead Pharma.
- Initial focus on paltusotine Phase 3 PATHFNDR program for acromegaly registration.
- Also overseeing commercial readiness for pipeline candidates CRN04777 and CRN04894.

## SEC filing metadata
- accession: 0000950170-22-002421
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2022-03-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000095017022002421/0000950170-22-002421-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000095017022002421/crnx-20220228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-002421
- JSON: https://secwatch.observer/filing/0000950170-22-002421.json
- Plain text: https://secwatch.observer/filing/0000950170-22-002421.txt

## Key facts
- Executive change
  James Hassard was appointed as Chief Commercial Officer at Crinetics Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Chief Commercial Officer
  source text: On March 1, 2022, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) announced the appointment of James Hassard as the Company’s Chief Commercial Officer, which was effective as of February 28, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658247/000095017022002421/0000950170-22-002421-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.